These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24620799)

  • 1. A reflection on fit-for-purpose metabolite investigation at different stages of drug development.
    Leclercq L
    Bioanalysis; 2014 Mar; 6(5):591-4. PubMed ID: 24620799
    [No Abstract]   [Full Text] [Related]  

  • 2. A tiered approach to address regulatory drug metabolite-related issues in drug development.
    Ma S; Chowdhury SK
    Bioanalysis; 2014 Mar; 6(5):587-90. PubMed ID: 24620798
    [No Abstract]   [Full Text] [Related]  

  • 3. An industry perspective on tiered approach to the investigation of metabolites in drug development.
    Huskey SE; Li W; Mangold JB; Flarakos J
    Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
    Korfmacher W
    Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
    [No Abstract]   [Full Text] [Related]  

  • 5. Mass spectrometry imaging in drug development.
    Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
    Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
    [No Abstract]   [Full Text] [Related]  

  • 6. A new era for proteomics.
    Kellie JF; Sikorski TW; An B; Chen Z; Moghieb AH; Busz MG; Szapacs ME; Angel TE
    Bioanalysis; 2019 Oct; 11(19):1731-1735. PubMed ID: 31617394
    [No Abstract]   [Full Text] [Related]  

  • 7. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technologies and strategies to characterize and quantitate metabolites in drug discovery and development.
    Ravindran S; Jadhav A; Surve P; Lonsane G; Honrao P; Nanda B
    Biomed Chromatogr; 2014 Nov; 28(11):1547-53. PubMed ID: 25175001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 10. Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.
    Prideaux B; Lenaerts A; Dartois V
    Curr Opin Chem Biol; 2018 Jun; 44():93-100. PubMed ID: 29957376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of evaluating the chemical structures and strategies to avoid pitfalls in quantitative bioanalysis.
    Licea-Perez H; Evans CA; Summerfield SG
    Bioanalysis; 2019 Jan; 11(2):85-101. PubMed ID: 30475061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation.
    Timmerman P
    Bioanalysis; 2014 Mar; 6(5):599-604. PubMed ID: 24620801
    [No Abstract]   [Full Text] [Related]  

  • 13. Free versus total ligand-binding assays: points to consider in biotherapeutic drug development.
    Yang J; Quarmby V
    Bioanalysis; 2011 Jun; 3(11):1163-5. PubMed ID: 21649490
    [No Abstract]   [Full Text] [Related]  

  • 14. Reflecting on a decade of metabolite screening and monitoring.
    Aubry AF; Christopher LJ; Wang J; Zhu M; Tirucherai G; Arnold ME
    Bioanalysis; 2014 Mar; 6(5):651-64. PubMed ID: 24620807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An introduction to hybrid ion trap/time-of-flight mass spectrometry coupled with liquid chromatography applied to drug metabolism studies.
    Liu ZY
    J Mass Spectrom; 2012 Dec; 47(12):1627-42. PubMed ID: 23280752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid chromatography coupled to mass spectrometry for metabolite profiling in the field of drug discovery.
    Saurina J; Sentellas S
    Expert Opin Drug Discov; 2019 May; 14(5):469-483. PubMed ID: 30810397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Biomarkers: The Field for the Development of Non-Pharmaceutical and Pharmaceutical Approaches to Diagnostics, Prevention and Treatment of Chronic Diseases.
    Sobenin IA; Orekhov AN
    Curr Pharm Des; 2016; 22(3):265-7. PubMed ID: 26719154
    [No Abstract]   [Full Text] [Related]  

  • 18. [Nontraditional approaches to biomedical screening (multifactorial diseases). Communication I].
    Piruzian LA; Mikhaĭlovskiĭ EM
    Fiziol Cheloveka; 2007; 33(5):138-48. PubMed ID: 18038673
    [No Abstract]   [Full Text] [Related]  

  • 19. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
    Obach RS
    Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.